Proteomic-Based Approaches for the Study of Ischemic Stroke
Proteomic-Based Approaches for the Study of Ischemic Stroke
复制标题
基于蛋白质组学的缺血性中风研究方法
DOI：
10.1007/s12975-019-00716-9
复制
发表时间：
2019
影响因子：
6.9
通讯作者：
Chen Gang
中科院分区：
文献类型：
--
作者：
Li Haiying;You Wanchun;Li Xiang;Shen Haitao;Chen Gang
缺血性中风是最常见的中风类型。尽管已经为建立准确的诊断和有效的治疗做出了广泛的努力，但缺血性卒中仍然是全球死亡的主要原因之一[1，2]。目前，基因组学提供了关于身体“能做什么”的信息，转录组学提供了关于细胞“会做什么”的信息，而蛋白质组学则告诉我们“正在发生什么”。蛋白质组学补充了基因组学和转录组学，并提供了有关蛋白质作为细胞主要功能介质的实施信息，例如其翻译后修饰及其与其他生物分子的相互作用[3]。在过去的几年中，研究重点是基因组学和转录组学，旨在发现缺血性卒中的新诊断或预后证据[4]。但是，缺血性脑卒中后脑细胞的状态与蛋白质功能最直接相关，这也是大多数药物干预的目标。因此，在蛋白水平的研究有利于深入描述缺血性脑卒中后神经元损伤。创新的高通量蛋白质组学技术可以帮助我们准确评估缺血后神经元损伤程度，研究药物作用机制，探索关键蛋白在神经元损伤中的作用。使用这些新兴的蛋白质组学技术，缺血性卒中的诊断和预后生物标志物可能会被确定。多年来，基于质谱（MS）的蛋白质组学使我们能够以非常高的精度获得大型分析数据集。本文就缺血性脑卒中的蛋白质组学研究进展作一综述。
Ischemic stroke is the most common type of stroke. Despite the fact that there have been extensive efforts for establishing accurate diagnose and efficient therapy, ischemic stroke continues to be one of the main causes of death worldwide [1, 2]. Currently, genomics provides information about what the body “can do,” transcriptomics provides information about what the cell “will do,” while proteomics tells us “what is happening.” Proteomics complements genomics and transcriptomics and provides information about the implementation of proteins as the main functional mediators of cells, such as their post-translational modification and their interactions with other biological molecules [3]. In the last years, studies focusing on genomics and transcriptomics aimed to discover new diagnostic or prognostic evidence for ischemic stroke [4]. However, the state of brain cells after ischemic stroke is most directly related to protein function, which is also the target of most drug intervention. Therefore, investigations at the protein level are favorable for the in-depth description of neuronal injury after ischemic stroke. Innovative high-throughput proteomics techniques can help us accurately evaluate the degree of neuronal injury after ischemia, study the mechanism of drug action, and explore the role of key proteins in neuronal injury. Using these emerging proteomics techniques, diagnostic and prognostic biomarkers for ischemic stroke may be identified. For years, mass spectrometry (MS)-based proteomics has enabled us to obtain large profiling datasets with very high precision. Here, the recent advances in proteomic researches in ischemic stroke are outlined.